Price Chart

Profile

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
URL http://www.adlainortye.com
Investor Relations URL https://ir.adlainortye.com/
HQ State/Province Zhejiang
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release Feb. 25, 2009
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
URL http://www.adlainortye.com
Investor Relations URL https://ir.adlainortye.com/
HQ State/Province Zhejiang
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release Feb. 25, 2009
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A